Title:Effect of Intranasal Administration of Galanin-like Peptide (GALP) on Body Weight and Hepatic Lipids Accumulation in Mice with Diet-induced Obesity
Volume: 23
Issue: 25
Author(s): Satoshi Hirako, Nobuhiro Wada, Haruaki Kageyama, Fumiko Takenoya, Hyounju Kim, Yuzuru Iizuka, Akiyo Matsumoto, Mai Okabe and Seiji Shioda*
Affiliation:
- Hoshi University School of Pharmacy and Pharmaceutical Sciences Global Research Center for Innovative Life Science, Peptide Drug Innovation, 2-4-41 Ebara, Shinagawa-ku, Tokyo 142-8501,Japan
Keywords:
GALP, fatty liver, lipid metabolism, high fat diet, DIO, triglycerides.
Abstract: Galanin-like peptide (GALP) is a neuropeptide involved in the regulation of food intake behavior,
body weight and energy metabolism. In previous studies, we demonstrated that the intranasal administration of
GALP has weight loss effects, although the mechanism of this action was not clarified. The aim of this study was
to demonstrate the functional significance of GALP on lipid metabolism in the liver. Mice were fed a high fat diet
to cause diet-induced obesity (DIO) and then administered GALP intranasally for 2 weeks (experimental), or
vehicle (control). Body weights, along with lipid levels in the plasma and liver, and lipid metabolism-related gene
expression in the liver were subsequently measured. Body weight gain was decreased by the GALP treatment
compared to the control group. Lipid droplet levels in hepatocytes and hepatic triglyceride levels were decreased
in the GALP group compared with the vehicle group, whereas hepatic fatty acid β-oxidation-related gene mRNA
levels were increased in the GALP group. These results suggest that the intranasal administration of GALP has an
inhibitory effect on lipid accumulation in the liver.
